Experienced in Autoimmune Hemolytic Anemia

Dr. Emad N. Ibrahim

Hematology Oncology | Oncology | Hematology
Faculty Physicians And Surgeons Of Llusm
81 Highland Springs Ave, 
Beaumont, CA 
 (145.8 mi)
Experienced in Autoimmune Hemolytic Anemia
Faculty Physicians And Surgeons Of Llusm
81 Highland Springs Ave, 
Beaumont, CA 
 (145.8 mi)
OverviewInsuranceLocationsClinical Research

Overview

Emad Ibrahim is a Hematologist Oncology specialist and an Oncologist in Beaumont, California. Dr. Ibrahim and is rated as an Experienced provider by MediFind in the treatment of Autoimmune Hemolytic Anemia. His top areas of expertise are Breast Cancer, Primary Immunodeficiency (PID), Paget Disease of the Breast, and Familial Colorectal Cancer.

His clinical research consists of co-authoring 72 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Oncology
Hematology
Licenses
Internal Medicine in CA
Hospital Affiliations
Redlands Community Hospital
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Locations

FACULTY PHYSICIANS AND SURGEONS OF LLUSM
81 Highland Springs Ave, Beaumont, CA 92223
Other Locations
FACULTY PHYSICIANS AND SURGEONS OF LLUSM
11234 Anderson St, Loma Linda, CA 92354

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

LUNAR: Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure
LUNAR: Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure
Enrollment Status: Completed
Publish Date: October 21, 2024
Intervention Type: Drug, Device
Study Drug: Immune checkpoint inhibitors or docetaxel
Study Phase: Phase 3
Double-blinded, Randomized, Adaptive Registrational Trial to Compare Effectiveness of Two Digital Software Medical Devices (Attune™ and Cerena™) as Interventions for Physical and Emotional Health in Adjunctive Oncology Treatment
Double-blinded, Randomized, Adaptive Registrational Trial to Compare Effectiveness of Two Digital Software Medical Devices (Attune™ and Cerena™) as Interventions for Physical and Emotional Health in Adjunctive Oncology Treatment
Enrollment Status: Terminated
Publish Date: September 13, 2022
Intervention Type: Device
Study Phase: Not Applicable
Phase 2, Open-Label, Dose-Ranging Study of SPI-2012 (HM10460A) or Pegfilgrastim Use for the Management of Neutropenia in Patients With Breast Cancer Who Are Candidates for Adjuvant and Neoadjuvant Chemotherapy With the Docetaxel + Cyclophosphamide (TC) Regimen
Phase 2, Open-Label, Dose-Ranging Study of SPI-2012 (HM10460A) or Pegfilgrastim Use for the Management of Neutropenia in Patients With Breast Cancer Who Are Candidates for Adjuvant and Neoadjuvant Chemotherapy With the Docetaxel + Cyclophosphamide (TC) Regimen
Enrollment Status: Completed
Publish Date: April 15, 2022
Intervention Type: Drug
Study Phase: Phase 2
A Multicenter, Open-Label, Randomized-Controlled Study of Abemaciclib, a CDK4 and 6 Inhibitor, in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer With Visceral Metastases
A Multicenter, Open-Label, Randomized-Controlled Study of Abemaciclib, a CDK4 and 6 Inhibitor, in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer With Visceral Metastases
Enrollment Status: Terminated
Publish Date: August 24, 2021
Intervention Type: Drug
Study Phase: Phase 4
A Randomized Phase 2 Trial of AM0010 in Combination With Pembrolizumab vs. Pembrolizumab Alone as First-Line (1L) Therapy in Patients With Stage IV / Metastatic Wild Type (WT) Non-Small Cell Lung Cancer and Tumors With High Expression of PD-L1 (> 50%)
A Randomized Phase 2 Trial of AM0010 in Combination With Pembrolizumab vs. Pembrolizumab Alone as First-Line (1L) Therapy in Patients With Stage IV / Metastatic Wild Type (WT) Non-Small Cell Lung Cancer and Tumors With High Expression of PD-L1 (> 50%)
Enrollment Status: Terminated
Publish Date: January 20, 2021
Intervention Type: Drug, Biological
Study Phase: Phase 2
A Randomized Phase 2 Trial of AM0010 in Combination With Nivolumab vs. Nivolumab Alone as Second-Line Therapy in Subjects With Stage IV / Metastatic Wild Type Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1
A Randomized Phase 2 Trial of AM0010 in Combination With Nivolumab vs. Nivolumab Alone as Second-Line Therapy in Subjects With Stage IV / Metastatic Wild Type Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1
Enrollment Status: Terminated
Publish Date: September 11, 2020
Intervention Type: Biological, Drug
Study Phase: Phase 2
A Single-Arm, Global, Phase 4 Study of Abemaciclib, a CDK 4 & 6 Inhibitor, in Combination With Nonsteroidal Aromatase Inhibitors (Anastrozole or Letrozole) in Participants With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Advanced Breast Cancer With Poor Prognostic Factors
A Single-Arm, Global, Phase 4 Study of Abemaciclib, a CDK 4 & 6 Inhibitor, in Combination With Nonsteroidal Aromatase Inhibitors (Anastrozole or Letrozole) in Participants With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Advanced Breast Cancer With Poor Prognostic Factors
Enrollment Status: Withdrawn
Publish Date: September 06, 2019
Intervention Type: Drug
Study Phase: Phase 4
View 6 Less Clinical Trials

72 Total Publications

Testing the efficacy of hormonal male contraception: a step in the right direction.
Testing the efficacy of hormonal male contraception: a step in the right direction.
Journal: Fertility and sterility
Published: December 23, 2024
Similar Doctors
Distinguished in Autoimmune Hemolytic Anemia
Dr. Constantin A. Dasanu
Hematology Oncology | Hematology | Oncology
Distinguished in Autoimmune Hemolytic Anemia
Dr. Constantin A. Dasanu
Hematology Oncology | Hematology | Oncology

Eisenhower Medical Center

39000 Bob Hope Dr, Suite 2, 
Rancho Mirage, CA 
 (33.0 mi)
760-837-8542
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Constantin Dasanu is a Hematologist Oncology specialist and a Hematologist in Rancho Mirage, California. Dr. Dasanu and is rated as a Distinguished provider by MediFind in the treatment of Autoimmune Hemolytic Anemia. His top areas of expertise are Vitamin B12 Deficiency Anemia, Pernicious Anemia, Neuroendocrine Tumor, Melanoma, and Bone Marrow Aspiration.

Distinguished in Autoimmune Hemolytic Anemia
Dr. Henry T. Tsai
Hematology Oncology | Hematology | Oncology
Distinguished in Autoimmune Hemolytic Anemia
Dr. Henry T. Tsai
Hematology Oncology | Hematology | Oncology

Eisenhower Medical Center

45280 Seeley Dr, 
La Quinta, CA 
 (40.0 mi)
760-610-7200
Languages Spoken:
English
Offers Telehealth

Henry Tsai is a Hematologist Oncology specialist and a Hematologist in La Quinta, California. Dr. Tsai and is rated as a Distinguished provider by MediFind in the treatment of Autoimmune Hemolytic Anemia. His top areas of expertise are Colorectal Cancer, Chronic Familial Neutropenia, Agranulocytosis, Bone Marrow Aspiration, and Advanced Bronchoscopy.

Advanced in Autoimmune Hemolytic Anemia
Dr. Andreea A. Nanci
Hematology Oncology | Hematology | Oncology
Advanced in Autoimmune Hemolytic Anemia
Dr. Andreea A. Nanci
Hematology Oncology | Hematology | Oncology

Uc Regents

101 The City Dr S, 
Orange, CA 
 (54.8 mi)
714-456-7002
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Andreea Nanci is a Hematologist Oncology specialist and a Hematologist in Orange, California. Dr. Nanci and is rated as a Distinguished provider by MediFind in the treatment of Autoimmune Hemolytic Anemia. Her top areas of expertise are Inflammatory Breast Cancer, Paget Disease of the Breast, Angiosarcoma, and Chronic Lymphocytic Leukemia (CLL).

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile